Abstract
Rectal gastrointestinal stromal tumors (GISTs) are uncommon, and the role of local excision versus a more extensive resection after the advent of effective targeted chemotherapy with imatinib is not known. Our aim is to present two cases of large anorectal GIST treated with local excision through a new anterolateral trans-sphincteric approach followed by adjuvant therapy with imatinib. Two patients (both males, 68 and 63 years old) presented at our institution with anorectal GIST in the period October–November 2010. Their medical records, pathology results, and imaging studies were retrospectively reviewed. Both patients presented with an anterior perianal mass. Imaging studies were characteristic of GIST originating in the lower rectum, circumscribed by a pseudocapsule, and protruding into the ischiorectal fossa. Both patients underwent local excision via an anterolateral trans-sphincteric approach. Both tumors were removed intact, with microscopically negative margins. The maximum tumor diameter was 8 and 9 cm, and the diagnosis of GIST was confirmed by positive CD117 and CD34 staining in both cases. Both tumors had a high (>5/50HPF) mitotic index. The patients had an uneventful postoperative course and were discharged on days 5 and 6. Both patients were started on imatinib 400 mg bid postoperatively. Postoperative magnetic resonance imaging and positron emission tomography computed tomography were carried out at 12 months and did not reveal any signs of recurrence. The patients are currently disease-free at 24 and 23 months of follow-up. In selected cases, complete excision of rectal GIST with negative margins is feasible via a trans-sphincteric approach. With the use of adjuvant therapy, which is currently advocated in all high-risk cases, it is possible that local excision with its reduced morbidity may become a viable alternative, especially in patients who would otherwise require abdominoperineal excision such as the two presented here. Prospective studies with longer follow-up are needed to confirm adequate oncologic results.
This is a preview of subscription content, log in via an institution to check access.
References
Conlon KC, Casper ES, Brennan MF (1995) Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 2:26–31
Hassan I, You YN, Dozois EJ et al (2006) Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Dis Colon Rectum 49:609–615
Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J (2001) Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 25:1121–1133
DeMatteo RP, Lewis JJ, Leung D, Mudran SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58
Yeh CY, Chen HH, Tang R, Tasi WS, Lin PY, Wang JY (2000) Surgical outcome after curative resection of rectal leiomyosarcoma. Dis Colon Rectum 43:1517–1521
Demetri GD (2008) Gastrointestinal stromal tumors. In: DeVita VT Jr, Lawrence TS, Rosenberg SA (eds) DeVita, Hellman, and Rosenberg’s Cancer: principles & practice of oncology vol 1, 8th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1204–1217
DeMatteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104
Miettinen M, Majidi M, Lasota J (2002) Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 38(Suppl 5):S39–S51
Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 8(Suppl 2):S1–S41
Gervaz P, Huber O, Bucher P, Sappino P, Morel P (2008) Trans-sacral (Kraske) approach for gastrointestinal stromal tumour of the lower rectum: old procedure for a new disease. Colorectal Dis 10:951–952
Hellan M, Maker VK (2009) Transvaginal excision of a large rectal stromal tumor: an alternative. Am J Surg 191:121–123
Wang JP, Wang T, Huang MJ, Wang L, Kang L, Wu XJ (2011) The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor. Am J Clin Oncol 34:314–316
Matsushima K, Kayo M (2007) Transsacral approach to resect a gastrointestinal stromal tumor in the rectum: report of two cases. Surg Today 37:698–701
Terkivatan T, den Hoed PT, Lange JF Jr, Koot VC, van Goch JJ, Veen HF (2005) The place of the posterior surgical approach for lesions of the rectum. Dig Surg 22:86–90
Williams NS, Murphy J, Knowles CH (2008) Anterior perineal PlanE for ultra-low anterior resection of the rectum (the APPEAR technique): a prospective clinical trial of a new procedure. Ann Surg 247:750–758
Machlenkin S, Pinsk I, Tulchinsky H et al (2011) The effect of neoadjuvant imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. Colorectal Dis 13:1110–1115
Jiang WZ, Guan GX, Lu HS (2011) Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. J Surg Oncol 104:760–764
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Centonze, D., Pulvirenti, E., Pulvirenti D’Urso, A. et al. Local excision with adjuvant imatinib therapy for anorectal gastrointestinal stromal tumors. Tech Coloproctol 17, 571–574 (2013). https://doi.org/10.1007/s10151-013-0976-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10151-013-0976-0